Latest Structure Therapeutics News & Updates
See the latest news and media coverage for Structure Therapeutics. We track all announcements, press releases, and industry mentions in real time, all in one place.
Clinical-stage biopharmaceutical company developing oral small molecule therapeutics
structuretx.com- Headquarters
- South San Francisco, United States
- Founded year
- 2017
- Company type
- Public company
- Number of employees
- 50–225
Latest news about Structure Therapeutics
Company announcements
-
Structure Therapeutics appoints Matthew Lang as COO and General Counsel
Lang brings over 15 years of biopharma experience in legal, strategy, and operations. He previously served at Metsera, Lyell Immunopharma, and Myovant.
-
Structure Therapeutics announces positive Phase 2 trial data
The data from the ACCESS II trial for aleniglipron supports Phase 3 preparation and offers a convenient oral option for obesity treatment.
-
Structure Therapeutics reports positive Phase 2 topline data
Aleniglipron achieves 16.3% placebo-adjusted weight loss at 44 weeks. Phase 3 initiation is on track for 2H 2026.
-
Structure Therapeutics reports Q4 and full-year 2025 financial results
Highlights positive Phase 2 aleniglipron data, $1.4B cash runway through 2028, and Phase 3 plans for 2H 2026.
Media coverage
-
Structure Therapeutics to Present Aleniglipron, Amylin and Combination Data at the American Diabetes Association 86th Scientific Sessions
Detailed price information for Structure Therapeutics Inc (GPCR-Q) from The Globe and Mail including charting and trades.
-
Structure Therapeutics Reports Positive Topline Data from Phase 2 ACCESS II Trial with Once-Daily Oral Small Molecule GLP-1 Receptor Agonist, Aleniglipron
Detailed price information for Structure Therapeutics Inc (GPCR-Q) from The Globe and Mail including charting and trades.
-
Structure Therapeutics Appoints Matthew Lang as Chief Operating Officer
Detailed price information for Structure Therapeutics Inc (GPCR-Q) from The Globe and Mail including charting and trades.
-
Weight Loss Drug-Maker Structure Therapeutics Stock Jumps On Eli Lilly News - Structure Therapeutics (NAS
Structure Therapeutics shares rose, likely driven by FDA approval of a competing obesity treatment, boosting sentiment.
Track Structure Therapeutics and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Structure Therapeutics competitors & trending companies
Browse news for competitors to Structure Therapeutics and other trending companies.
Pila Pharma
BioAge Labs
Wave Life Sciences
Sironax
Aperture Therapeutics
Attentive
Klaviyo
Twilio
Insider One
Zeta Global
Iterable
Braze
Optimove
Bluecore
BlueConic
Amperity
Wero
BLIK
EPI
Swish
Affirm
Brite Payments
TCS
Overview Energy
Adfin
Ineffable Intelligence
Mechanize
Hexatronic
Alimak Group
Lindab Group
NYAB
Noon Energy
Nordan AI
Mips